With all of the pipeline success we're seeing from the Big Biotech stocks lately, Big Pharma's more hit-and-miss recent drug development track record hasn't gone unnoticed.
Today, Pfizer announced that it was halting a phase 3 trial for inotuzumab ozogamicin in aggressive non-Hodgkin's lymphoma, as it wasn't showing any survival benefit over the control group. It was a surprise cancellation, and there had been a lot of enthusiasm around this drug, which targeted an antigen found in more than 90% of b-cell malignancies.
In this video, health-care analyst David Williamson discusses what this drug failure means for Pfizer, its competitors, and its investors.
